Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
8
×
biotech
8
×
clinical trials
8
×
life sciences
national blog main
national top stories
new york top stories
boston blog main
national
new york blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
startups
abbvie
bristol-myers squibb
cancer
cancer immunotherapy
eli lilly
gene therapy
zolgensma
alzheimer's disease
What
bio
roundup
drug
new
biotech
ceo
days
drugs
fda
ipo
medicines
news
research
week
acquisitions
aims
alliance
alzheimer’s
america
announced
annual
approval
approved
assessed
atrophy
attention
august
backed
biogen
biogen’s
biopharmaceutical
bristol
busy
buy
calls
cause
changing
collabs
color
communities
Language
unset
Current search:
biotech
×
" clinical trials "
×
biogen
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More